-
1
Longitudinal mutational analysis in hydroxycarbamide-resistant/intolerant essential thrombocythemia treated on the majic-ET study
Published 2018“…American Society of Hematology…”
Conference item -
2
Correlation between treatment outcomes, baseline characteristics and molecular responses in the Majic study which compared Ruxolitinib to best available therapy in essential thromb...
Published 2016“…American Society of Hematology…”
Conference item -
3
A novel integrated cytogenetic and genomic classification refines risk stratification in pediatric acute lymphoblastic leukemia.
Published 2014“…American Society of Hematology…”
Journal article -
4
Ruxolitinib versus best available therapy for ET intolerant or resistant to hydroxycarbamide in a randomized trial
Published 2017“…American Society of Hematology…”
Journal article -
5
Integration of genetic and clinical risk factors improves prognostication in relapsed childhood B-cell precursor acute lymphoblastic leukaemia.
Published 2016“…American Society of Hematology…”
Journal article